NASC Can B Corp
Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1509957 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (2023Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.8%
TTM net income YoY34.8%
TTM EPS YoY81.6%
Revenue 3-yr CAGR8.0%
Net income 3-yr CAGR—
Margins
Gross margin16.6%
Operating margin-347.3%
Net margin-451.7%
FCF margin-61.2%
EBITDA margin-282.9%
Returns
ROE-2,317.5%
ROA-75.8%
ROIC (approx.)-1,613.4%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets118.3%
Debt / equity—
Current ratio0.45x
Interest coverage-2.98x
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-65.7%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.16M | $6.69M |
| Cost of revenue | $1.80M | $4.07M |
| Gross profit | $358,698 | $2.61M |
| SG&A expense | — | $926,696 |
| Operating income | -$7.49M | -$14.17M |
| Interest expense | $2.51M | $902,130 |
| Pretax income | -$9.73M | -$14.92M |
| Income tax | $9,596 | $793 |
| Net income | -$9.74M | -$14.92M |
| EBITDA | -$6.10M | -$12.76M |
| EPS (basic) | -0.77 | -4.18 |
| EPS (diluted) | -0.77 | -4.18 |
| Weighted avg. shares (diluted) | 12.59M | 3.57M |
| Balance sheet | ||
| Cash & equivalents | $34,006 | $73,194 |
| Receivables | $3.72M | $6.59M |
| Inventory | $1.62M | $2.02M |
| Current assets | $5.38M | $8.70M |
| PP&E, net | $4.11M | $5.43M |
| Intangibles | $95,144 | $107,144 |
| Total assets | $10.13M | $15.56M |
| Current liabilities | $11.98M | $12.42M |
| Total liabilities | $11.98M | $12.86M |
| Shareholders' equity | -$1.86M | $2.70M |
| Shares outstanding | 32.75M | 2.83M |
| Cash flow statement | ||
| Operating cash flow | -$1.30M | -$3.95M |
| Capital expenditure | $15,000 | — |
| Free cash flow | -$1.32M | — |
| Investing cash flow | -$84,631 | — |
| Financing cash flow | $1.35M | $3.57M |
| Depreciation & amortization | $1.39M | $1.41M |
| Stock-based compensation | $1.45M | $5.06M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.